Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 2, 1998, Pages 331-334

  Goldberg, Zelanna I ^a,b   Cummings, Bernard J ^a,b   Chapman, William B ^b   Klamut, Henry J ^a,b   Rauth, Andrew M ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anal canal carcinoma; DT diaphorase; Mitomycin C; Polymerase chain reaction

Indexed keywords

FLUOROURACIL; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ALLELE; ANUS CARCINOMA; ARTICLE; BASE MISPAIRING; BIOPSY; CONTROLLED STUDY; DNA POLYMORPHISM; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0032171046     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00234-X     Document Type: Article

References (22)

1. Nigro N.D., Vaitkevicius V.K., Considine B. Combined therapy for cancer of the anal canal A preliminary report . Dis Colon Rectum. 2:1974;354-357.
2. Cummings B.J., Keane T.S., O'Sullivan B., Wong C.S., Catton C.N. Epidermoid anal cancer Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin-C . Int J Radiat Oncol Biol Phys. 21:1991;1115-1125.
3. Flam M., John M., Pajak T.F., Petrelli N., Myerson R., Doggett S., Quivey J., Rotman M., Kerman H., Coia L., Murray K. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive non-surgical treatment of epidermoid carcinoma of the anal canal Results of a phase III randomized intergroup study . J Clin Oncol. 14:1996;2327-2539.
4. Epidermoid anal cancer results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin . Lancet. 348:1996;1049-1054.
5. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., Peiffert D., van Glabbeke M., Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer radiotherapy and gastrointestinal cooperative groups . J Clin Oncol. 15:1997;2040-2049.
6. Sartorelli A.C., Hadnick W.F., Belcourt M.F., Tomasz M., Haffty B., Fischer J.J., Rockwell S. Mitomycin C A prototype bioreductive agent . Oncol Res. 6:1994;501-508.
7. Rauth A.M., Marshall R.S., Kuehl B.L. Cellular approaches to bioreductive drug mechanisms. Cancer Met Rev. 12:1993;153-164.
8. Rockwell S. Use of hypoxia-directed drugs in the therapy of solid tumours. Semin Oncol. 19:(Suppl. 11):1992;29-40.
9. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., Lewis A.D. Reductase enzyme expression across the National Cancer Institute tumour cell line panel; correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst. 88:1996;259-269.
10. Ross D., Beall H., Traver R.D., Siegel D., Phillips R.M., Bison N.W. Bioactivation of quinones by DT-diaphorase Molecular, biochemical and chemical studies . Oncol Res. 6:1994;493-500.
11. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., Gibson N.W. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity . Cancer Res. 52:1992;797-802.
12. 1) gene structure and induction by dioxin. Biochem. 30:1991;10647-10653.
13. Jaiswal A., McBride O.W., Adesnik M., Nebert D.W. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16. J Biol Chem. 263:1988;13572-13578.
14. Kuehl B.L., Paterson J.W.E., Peacock J.W., Paterson M.C., Rauth A.M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 72:1995;555-561.
15. Edwards Y.H., Potter J., Hopkinson D.A. Human FAD-dependent NAD(P)H diaphorase. Biochem J. 187:1980;429-436.
16. Eickelmann P., Schulz W.A., Rohde D., Schmitz-Drager B., Sies H. Loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem Hoppe-Seyler. 375:1994;439-445.
17. Rosvold E.A., McGlynn K.A., Lustbader E.D., Buetow R.H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogen. 5:1995;199-206.
18. Traver R.D., Siegel D., Beall H.D., Phillips R.M., Gibson N.W., Franklin W.A., Ross D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer. 75:1997;69-75.
19. Wiencke J.K., Spitz M.R., McMillan A., Kelsey K.T. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of NAD(P)H quinone oxidoreductase polymorphism . Cancer Epidemiol Biomarkers Prev. 6:1997;87-92.
20. Kelsey K.T., Ross D., Traver R.D., Christiani D.C., Zuo Z.-F., Spitz M.R., Wang M., Xu X., Lee B.-K., Schwartz B.S., Wiencke J.K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer. 76:1997;852-854.
21. Greer CE, Peterson SL, Kiviat NB, Manos MM. PCR Amplification from paraffin-embedded tissues: Effects of fixative and fixation time. Am J Clin Pathol 1991;95:2:117-124.
22. Klamut H.J., Gangopadhyay S.B., Worton R.G., Ray P.N. Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene. Molec Cell Biol. 10:1990;193-205.